Curapel Overview

  • Founded
  • 2011

Founded
  • Status
  • Private

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $1.96M

  • Investors
  • 6

Curapel General Information

Description

Developer of specialty pharmaceutical products intended for the treatment of common skin conditions. The company's healthcare process develops oral and cream-based medicinal products for the treatment of conditions like skin pigmentation, eczema, atopic dermatitis, lightening and psoriasis, enabling the medical community and patients to meet and resolve unmet clinical needs.

Contact Information

Website
www.curapel.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Pharmaceuticals
Other Industries
Personal Products
Drug Discovery
Primary Office
  • Stuart House
  • Chepstow NP16 5HH
  • Wales, United Kingdom
+44 07866 000000

Curapel Timeline

2019202020212022
Financing Round

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Curapel Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC 01-May-2021 $1.96M 00.000 Completed Generating Revenue
6. Later Stage VC 01-Mar-2020 00000 00.000 00.000 Completed Generating Revenue
5. Angel (individual) 05-Sep-2017 00000 00.000 00.000 Completed Startup
4. Grant 01-May-2017 00000 00000 Completed Generating Revenue
3. Angel (individual) 15-Aug-2016 00000 00000 00.000 Completed Startup
2. Angel (individual) 14-Jun-2014 $336K $336K 00.000 Completed Startup
1. Grant $36.2K Completed Startup
To view Curapel’s complete valuation and funding history, request access »

Curapel Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
Ordinary 000,000 00.000000 00.00 00.00 00 00.00 0.000
Preferred Ordinary 0,000,000 00.000000 00.00 00.00 00 00.00 0.000
Preferred Ordinary 2,333,333 $0.012974 $0.19 $0.19 1x $0.19 12.06%
Ordinary 2,353,329 $0.000013 $0.19 $0.19 1x $0.19 12.17%
To view Curapel’s complete cap table history, request access »

Curapel Patents

Curapel Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
ES-2875275-T3 Exothermic topical devices for the delivery of drugs and cosmetics to the skin Active 30-Nov-2015 0000000000
GB-2544813-A Devices and methods for delivering pharmaceuticals and cosmetics to the skin Granted 30-Nov-2015 0000000000 0
EP-3413867-A1 Exothermic topical devices for delivering pharmaceuticals and cosmetics to the skin Granted 30-Nov-2015 0000000000
GB-201521111-D0 Devices and methods for delivering pharmaceuticals and cosmetics to the skin Granted 30-Nov-2015 0000000000
US-20180353438-A1 Exothermic topical devices for delivering pharmaceuticals and cosmetics to the skin Abandoned 30-Nov-2015 A61K9/7092
To view Curapel’s complete patent history, request access »

Curapel Executive Team (4)

Name Title Board Seat Contact Info
Peter Luebcke Ph.D Chief Executive Officer
Neil Gibbs Ph.D Co-Founder, Chief Scientific Officer & Board Member
Alan Williams Finance Director
You’re viewing 3 of 4 executive team members. Get the full list »

Curapel Board Members (2)

Name Representing Role Since
Neil Gibbs Ph.D Curapel Co-Founder, Chief Scientific Officer & Board Member 000 0000
Terry Sadler Self Chairman 000 0000
To view Curapel’s complete board members history, request access »

Curapel Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Development Bank of Wales Venture Capital Minority 000 0000 000000 0
Meltwind Venture Capital Minority 000 0000 000000 0
Innovate UK Government 000 0000 000000 0
Lancaster Capital Angel Group Minority 000 0000 000000 0
Biotechnology and Biological Science Research Council Limited Partner 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »